PharmaFluidics NV

PharmaFluidics NV is a biotechnology company specializing in innovative chromatography solutions, focusing on enhancing protein analysis through low-flow HPLC and UHPLC technologies. Founded in 2010 and headquartered in Ghent, Belgium, PharmaFluidics NV develops specialized chromatography products aimed at improving protein analysis. The company has successfully raised funding through three deals, with the most recent funding round occurring on January 11, 2018, where they secured EUR 7. 3 million from investors including Innovation Fund, PMV, Qbic Fund, and new participant SFPI-FPIM.

This brought the total amount raised to EUR 7. 3 million. PharmaFluidics NV offers cutting-edge low-flow chromatography products, particularly focusing on low-flow HPLC and UHPLC columns designed for high sensitivity and resolution in protein analysis. Their product lineup includes specialized cartridges and columns, such as the OptiSpray µPAC Neo cartridges and EASY-Spray PepMap Neo UHPLC columns, catering to the needs of academic research institutions, pharmaceutical companies, and clinical laboratories.

These products are essential for fields such as proteomics, metabolomics, and lipidomics research, with a focus on applications that require minimal sample volumes. In 2020, PharmaFluidics NV reported a revenue of EUR 1,635,308. 60 with an EBITDA of EUR -1,331,092. 30, indicating operational challenges that the company is addressing as it continues to innovate and expand its offerings.

PharmaFluidics NV plans to utilize the recent EUR 7. 3 million funding to develop and launch new chromatography products aimed at enhancing protein analysis capabilities. The company is eyeing expansion into key markets in North America and Asia-Pacific by 2025, where the demand for advanced analytical solutions is growing. The funds will support research and development initiatives to create innovative solutions tailored to these regions, ensuring a strong market presence in the global biotechnology landscape.